Fasting Study of Cilostazol Tablets 100 mg and Pletal® Tablets 100 mg
Study Details
Study Description
Brief Summary
The objective of this study was to investigate the bioequivalence of Mylan's cilostazol 100 mg tablets and Otsuka's Pletal® 100 mg tablets following a single, oral 100 mg(1 x 100 mg) dose administered under fasting conditions.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: 1 Cilostazol Tablets 100 mg |
Drug: Cilostazol Tablets 100 mg
100mg, single dose fasting
|
| Active Comparator: 2 Pletal® Tablets 100 mg |
Drug: Pletal® Tablets 100 mg
100 single dose fasting
|
Outcome Measures
Primary Outcome Measures
- Bioequivalence [within 30 days]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age: 18 years and older.
-
Sex: Male and/or non-pregnant, non-lactating female.
-
Women of childbearing potential must have negative serum beta human chorionic gonadotropin (beta-HCG) pregnancy tests performed within 14 days prior to the start of the study and on the evening prior to each dose administration. If dosing is scheduled on weekends, the HCG pregnancy test should be given within 48 hours prior to dosing of each study period. An additional serum (beta-HCG) pregnancy test will be performed upon completion of the study.
-
Women of childbearing potential must practice abstinence or be using an acceptable form of contraception throughout the duration of the study. No hormonal contraceptives or hormone replacement therapy are permitted in this study. Acceptable forms of contraception include the following:
-
intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or
-
barrier methods containing or used in conjunction with a spermicidal agent, or
-
surgical sterility (tubal ligation, oophorectomy or hysterectomy) or postmenopausal accompanied with a documented postmenopausal course of at least one year.
-
During the course of the study, from study screen until study exit - including the washout period, women of childbearing potential must use a spermicide containing barrier method of contraception in addition to their current contraceptive device. This advice should be documented in the informed consent form.
-
Weight: At least 60 kg (132 lbs) for men and 48 kg (106 lbs) for women and all subjects within 15% of Ideal Body Weight (IBW), as referenced by the Table of "Desirable Weights of Adults" Metropolitan Life Insurance Company, 1999 (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).
-
All subjects should be judged normal and healthy during a pre-study medical evaluation (physical examination, laboratory evaluation, hepatitis B and hepatitis C tests, HIV test, 12-lead ECG, and urine drug screen including amphetamine, barbiturates, benzodiazepines, cannabinoid, cocaine, opiate, phencyclidine, and methadone) performed within 14 days of the initial dose of study medication
Exclusion Criteria:
-
Institutionalized subjects will not be used.
-
Social Habits:
-
Use of any tobacco products within 1 year of the start of the study.
-
Ingestion of any alcoholic, caffeine- or xanthine-containing food or beverage within 48 hours prior to the initial dose of study medication.
-
Ingestion of any vitamins or herbal products within 7 days prior to the initial dose of the study medication.
-
Any recent, significant change in dietary or exercise habits.
-
A positive test for any drug included in the urine drug screen.
-
History of drug and/or alcohol abuse.
-
Medications:
-
Use of any prescription or over-the-counter (OTC) medications within 14 days prior to the initial dose of study medication.
-
Use of any hormonal contraceptives and hormone replacement therapy within 3 months prior to study medication dosing.
-
Use of any medication known to alter hepatic enzyme activity within 28 days prior to the initial dose of study medication.
-
Diseases:
-
History of any significant cardiovascular (especially congestive heart failure), hepatic, renal, pulmonary, hematologic, gastrointestinal, endocrine, immunologic, dermatologic or neurologic disease.
-
Acute illness at the time of either the pre-study medical evaluation or dosing.
-
A positive HIV, hepatitis B, or hepatitis C test.
-
Abnormal and clinically significant laboratory test results:
-
Clinically significant deviation from the Guide to Clinically Relevant Abnormalities (See Part II ADMINISTRATIVE ASPECTS OF BIOEQUIVALENCE PROTOCOLS).
-
Abnormal and clinically relevant ECG tracing.
-
Donation or loss of a significant volume of blood or plasma (> 450 mL) within 28 days prior to the initial dose of study medication.
-
Subjects who have received an investigational drug within 30 days prior to the initial dose of study medication.
-
Allergy or hypersensitivity to cilostazol or any other related products.
-
History of difficulties in swallowing, or any gastrointestinal disease which could affect the drug absorption.
-
Consumption of grapefruit or any grapefruit containing products within 7 days prior to drug administration.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Gateway Medical Research, Inc. | St. Charles | Missouri | United States | 63301 |
Sponsors and Collaborators
- Mylan Pharmaceuticals Inc
Investigators
- Principal Investigator: Walter A Parham, M.D., Cetero Research, San Antonio
Study Documents (Full-Text)
None provided.More Information
Additional Information:
- Mylan Pharmaceuticals Inc. - Clinical Trial Results
- Daily Med - posting of most recent submitted labelling to the Food and Drug Administration (FDA) and currently in use
- Recalls, Market Withdrawals and Safety Alerts
Publications
None provided.- CILO-0395